Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Arbutus Biopharma Cp (ABUS)
Arbutus Biopharma Cp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 487,713
  • Shares Outstanding, K 162,571
  • Annual Sales, $ 39,020 K
  • Annual Income, $ -69,460 K
  • 60-Month Beta 2.26
  • Price/Sales 12.33
  • Price/Cash Flow N/A
  • Price/Book 3.24
Trade ABUS with:

Options Overview Details

View History
  • Implied Volatility 59.83% ( +59.83%)
  • Historical Volatility 35.01%
  • IV Percentile 8%
  • IV Rank 12.69%
  • IV High 214.58% on 09/27/22
  • IV Low 37.34% on 10/05/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 572
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 32,685
  • Open Int (30-Day) 36,782

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.15
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.57 +16.73%
on 02/27/23
3.08 -2.60%
on 03/22/23
+0.35 (+13.21%)
since 02/24/23
3-Month
2.15 +39.53%
on 01/05/23
3.08 -2.60%
on 03/22/23
+0.61 (+25.52%)
since 12/23/22
52-Week
1.85 +62.16%
on 09/23/22
3.22 -6.83%
on 04/04/22
-0.02 (-0.66%)
since 03/24/22

Most Recent Stories

More News
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 1.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 3.00 (+1.35%)
AKYA : 7.88 (+2.47%)
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 38.78% and 7.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ADCT : 1.9200 (-3.03%)
ABUS : 3.00 (+1.35%)
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

KYMR : 29.33 (+1.49%)
ABUS : 3.00 (+1.35%)
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

VCEL : 28.97 (+0.56%)
ABUS : 3.00 (+1.35%)
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 3.00 (+1.35%)
HGEN : 0.1370 (+1.56%)
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 3.00 (+1.35%)
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALBO : 44.15 (-0.23%)
ABUS : 3.00 (+1.35%)
Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript

ABUS earnings call for the period ending June 30, 2022.

ABUS : 3.00 (+1.35%)
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 3.00 (+1.35%)
ITCI : 46.73 (+1.83%)
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway...

ABUS : 3.00 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 3.18
2nd Resistance Point 3.09
1st Resistance Point 3.05
Last Price 3.00
1st Support Level 2.92
2nd Support Level 2.83
3rd Support Level 2.79

See More

52-Week High 3.22
Last Price 3.00
Fibonacci 61.8% 2.70
Fibonacci 50% 2.54
Fibonacci 38.2% 2.37
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar